Bullish & Foolish
Full BRTX fundamentals All 466 on the Survival Watch

BRTXBIORESTORATIVE THERAPIES, INC.

Is Biorestorative Therapies struggling financially?

Yes, by its own account. Biorestorative Therapies told the SEC on 14 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed May 2026

15/100

Critical

Sector
Biotech/Pharma
Market cap
$5.5M
Source filing
10-Q 14 May 2026
Balance sheet
31 Mar 2026

Cash runway

  • 2months

    If the burn speeds up

    Empty by May 2026

  • 4months

    If it eases off

    Empty by Jul 2026

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$3.1M

÷

Cash burned over the last 12 months

$10.9M

What Biorestorative Therapies told the SEC

…it executes its development plans during 2026 and beyond, as well as other potential strategic and business development initiatives. These conditions raise substantial doubt about the Company’s ability to continue as a going concern for at least twelve months after the issuance date of these financial statements. The Company has previously funded, and plans to continue funding, these losses primarily through…

BIORESTORATIVE THERAPIES, INC., Form 10-Q, filed 14 May 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • 112.1% share-count increase The company issued stock. Each share now owns 52.9% less of the business than a year ago, before any change in the price.
  • Cash burn is narrowing It is spending 29% less cash per year than it was, so the runway above is lengthening rather than shortening.

Other Biotech/Pharma companies that filed the doubt